← Human Trials & Peer-Reviewed Studies
beta-blockade, atrial natriuretic peptide and exercise
Plain-language guide to PMID 8688991 (1996): double-blind randomized controlled trial study of ANP (Atrial Natriuretic Peptide) in 15 volunteers.
Key Facts
- PMID
- 8688991
- Journal
- International journal of clinical pharmacology and therapeutics
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Kantola I et al. (6 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.
Changes in the release of atrial natriuretic peptide (ANP) and vasopressin (VP) may contribute to the final outcome of beta-adrenoceptor blocking therapy.
The researchers noticed clear differences in the animal beta 1- and beta 2-receptor occupancy between these agents.
Who Took Part
The abstract describes 15 volunteers taking part.
The age groups tagged for this paper are adults, men only.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The volunteers were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.
Neither the volunteers nor the staff measuring them knew who was on ANP (Atrial Natriuretic Peptide), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with ANP (Atrial Natriuretic Peptide) could be set against what happens without it.
In the crossover set-up each of the volunteers took both ANP (Atrial Natriuretic Peptide) and the comparison in turn, acting as their own control.
What Was Measured
Changes in the release of atrial natriuretic peptide (ANP) and vasopressin (VP) may contribute to the final outcome of beta-adrenoceptor blocking therapy.
The subject headings attached to it are Adrenergic alpha-Agonists, Adrenergic beta-Antagonists, Atenolol, Atrial Natriuretic Factor, Epinephrine, Exercise Test and Norepinephrine.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 15 volunteers.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1996 (International journal of clinical pharmacology and therapeutics), a journal based in Germany.
More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.
Our Notes on the Compound
ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.